Trials / Terminated
TerminatedNCT04582539
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB000928 | INCB000928 will be administered once daily. |
Timeline
- Start date
- 2021-08-19
- Primary completion
- 2024-08-15
- Completion
- 2024-08-15
- First posted
- 2020-10-09
- Last updated
- 2025-10-22
- Results posted
- 2025-10-22
Locations
15 sites across 3 countries: United States, France, Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04582539. Inclusion in this directory is not an endorsement.